Drug Approvals
(BANM, US Adopted Name, rINNM)
Synonyms: Feksofenadiinihydrokloridi; Fexofenadina, hidrocloruro de; Fexofenadinhydroklorid; Fexofenadini Hydrochloridum; MDL-16455A; Terfenadine Carboxylate Hydrochloride
BAN: Fexofenadine Hydrochloride [BANM]
USAN: Fexofenadine Hydrochloride
INN: Fexofenadine Hydrochloride [rINNM (en)]
INN: Hidrocloruro de fexofenadina [rINNM (es)]
INN: Fexofénadine, Chlorhydrate de [rINNM (fr)]
INN: Fexofenadini Hydrochloridum [rINNM (la)]
INN: Фексофенадина Гидрохлорид [rINNM (ru)]
Chemical name: (±)-p-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-piperidino]butyl}-αmethylhydratropic acid hydrochloride
Molecular formula: C32H39NO4,HCl =538.1
CAS: 138452-21-8
ATC code: R06AX26
Pharmacopoeias. In Europe and US.
European Pharmacopoeia, 6th ed. (Fexofenadine Hydrochloride). A white or almost white powder. Slightly soluble in water freely soluble in methyl alcohol very slightly soluble in acetone. It exhibits polymorphism.
The United States Pharmacopeia 31, 2008 (Fexofenadine Hydrochloride). Store at a temperature of 20° to 25°, excursions permitted between 15° and 30°. Protect from light.
Adverse Effects and Precautions
As for the non-sedating antihistamines in general.
Arrhythmias. A 67-year-old man suffered syncope after taking fexofenadine 180 mg daily for 2 months. His ECG showed an abnormally prolonged QT interval which shortened once fexofenadine was stopped, although the interval tended to be long even without drug therapy. Nonetheless rechallenge was positive. The manufacturers of fexofenadine have commented that the patient was at risk of developing arrhythmias before taking the drug.
The ECG effects of fexofenadine have been studied in normal subjects and doses of up to 480 mg daily [4 times the recommended dose for seasonal allergic rhinitis] did not prolong the QT interval.
Breast feeding. No adverse effects have been seen in breastfed infants whose mothers were receiving fexofenadine, and the American Academy of Pediatrics considers that it is therefore usually compatible with breast feeding.
See also under Adverse Effects and Precautions, in Terfenadine.
Psoriasis. Exacerbation of psoriasis has been reported in association with the use of fexofenadine.
Interactions
As for the non-sedating antihistamines in general.
Plasma concentrations of fexofenadine have been increased when given with erythromycin or ketocona-zole, but, unlike terfenadine, licensed product information states that this was not associated with adverse effects on the QT interval.
Antacids containing aluminium and magnesium hydroxide have reduced the absorption of fexofenadine. Fruit juices including grapefruit may reduce the bioa-vailability of fexofenadine and use together should be avoided.
Pharmacokinetics
Fexofenadine is rapidly absorbed after oral doses with peak plasma concentrations being reached in 2 to 3 hours. It is about 60 to 70% bound to plasma proteins. About 5% of the total dose is metabolised, mostly by the intestinal mucosa, with only 0.5 to 1.5% of the dose undergoing hepatic biotransformation by the cyto-chrome P450 system. Elimination half-life of about 14 hours has been reported although this may be prolonged in patients with renal impairment. Excretion is mainly in the faeces with only 10% being present in the urine. Fexofenadine does not appear to cross the blood-brain barrier.
Fexofenadine is a metabolite of terfenadine and as such has been detected in breast milk after the administration of terfenadine.
Uses and Administration
Fexofenadine, an active metabolite of terfenadine, is a non-sedating antihistamine. It does not possess significant sedative or antimuscarinic actions. Fexofenadine is used as the hydrochloride in the symptomatic relief of allergic conditions including seasonal allergic rhinitis and chronic urticaria.
In the UK a dose of fexofenadine hydrochloride 120 mg once daily is given orally in the treatment of seasonal allergic rhinitis the recommended dose in chronic idiopathic urticaria is 180 mg once daily. US licensed product information suggests a dose of 60 mg twice daily or 180 mg once daily for both indications.
Fexofenadine is also used with a decongestant such as pseudoephedrine hydrochloride.
For doses in children or in patients with renal impairment, see below.
Administration in children. Fexofenadine hydrochloride is used in children for the treatment of seasonal allergic rhinitis in an oral dose of 30 mg twice daily in the UK it is licensed for use in children aged 6 to 11 years whereas in the USA it may be used in children as young as 2 years.
In the USA, fexofenadine is also licensed for use in paediatric chronic idiopathic urticaria. The dose in children aged 6 months to less than 2 years is 15 mg twice daily older children may be given 30 mg twice daily.
For suggested doses in children with renal impairment see below.
Administration in renal impairment. US licensed product information recommends that initial oral doses of fexofenadine hydrochloride in adults with renal impairment should be reduced to 60 mg once daily. In children with renal impairment, the initial dose should be reduced to 30 mg once daily in patients aged 2 to 11 years, and to 15 mg once daily in children aged 6 months to less than 2 years.
UK product information advises that fexofenadine should be given with caution to patients with renal impairment however, it also states that dose adjustment is not considered to be necessary in such patients.
Preparations
The United States Pharmacopeia 31, 2008: Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets Fexofenadine Hydrochloride Capsules Fexofenadine Hydrochloride Tablets.
Proprietary Preparations
Argentina: Alerfedine Allegra Fexofen †
Australia: Fexotabs Telfast Xergic
Austria: Telfast
Belgium: Telfast
Brazil: Allegra Altiva
Canada: Allegra
Chile: Aerodan Alexia Allegra Fenax
Czech Republic: Afexil Ewofex Telfast
Denmark: Telfast
Finland: Telfast
France: Telfast
Germany: Telfast
Hong Kong: Telfast
Hungary: Altiva Telfast
India: Alernexf Allegra Fexigra Fexofen Fexova Odifex
Indonesia: Telfast
Ireland: Telfast
Israel: Telfast
Italy: Kalicet † Telfast
Malaysia: Telfast
Mexico: Allegra
The Netherlands: Telfast
Norway: Telfast
New Zealand: Telfast Xergic
Philippines: Telfast
Poland: Telfast
Portugal: Telfast
Russia: Fexadin Telfast
South Africa: Telfast
Singapore: Telfast
Spain: Telfast
Sweden: Telfast
Switzerland: Telfast
Thailand: Fenafex Telfast
Turkey: Fexadyne Fexofen Telfast
UK: Telfast
USA: Allegra
Venezuela: Allegra Fexidine Fexoril Rinolast
Multi-ingredient
Argentina: Alerfedine D Allegra-D
Australia:: Telfast Decongestant
Brazil: Allegra-D
Canada: Allegra-D
Chile: Alexia D Allegra-D
Hong Kong: Telfast-D
Indonesia: Telfast Plus
Malaysia: Altiva-D Telfast-D
Mexico: Allegra-D
New Zealand: Telfast Decongestant †
Singapore: Telfast-D
USA: Allegra-D
Venezuela: Allegra-D Rinolast D